Divya J Shekhar and Manu BalachandranThe month of November brought some much-needed glimmer of hope in a rather painful year.It all began with New York-based pharmaceutical giant Pfizer announcing that its vaccine candidate BNT162b2, developed in partnership with Mainz-based BioNTech, showed 90 percent effectiveness in preventing the coronavirus. A week later, 10-year-old pharmaceutical company Moderna announced that its coronavirus vaccine was 94.5 percent effective in preventing the virus. Moderna had given 15,000 participants their vaccine, of which only five developed Covid-19 with none of the five becoming severely ill.Close The announcements were followed by claims from the Russian health ministry that its vaccine Sputnik-V showed 95 percent efficacy, while UK-based pharmaceutical giant AstraZeneca announced that its vaccine, currently being manufactured in large doses at the Pune-based Serum Institute of India, showed up to 90 percent efficacy in preventing the virus. Two days later, AstraZeneca acknowledged an error in the manufacturing process, raising concerns about the efficacy. COVID-19 Vaccine Frequently Asked Questions View more How does a vaccine work? A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd… Read full this story
- India’s immunisation drive: Battling diseases, ensuring a healthy future
- Government envisages $100-billion biomanufacturing hub
- What's new in the world of wellness? AI to help the differently-abled
- The good, the bad and the ugly in global health in 2019
How will India vaccinate 1.3 billion people? have 255 words, post on www.moneycontrol.com at November 29, 2020. This is cached page on Business Breaking News. If you want remove this page, please contact us.